SCHEMBL3482512

SCHEMBL3482512

CCCc1ccccc1[SiH](Cl)Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.33
ADRA2B P18089 3/20 0.33
ADRA2C P18825 3/20 0.33
ADRA2A P08913 2/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
HTR1A P08908 2/20 0.32
KDM4E B2RXH2 3/20 0.31
GAA P10253 3/20 0.31
TAAR1 Q96RJ0 2/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 2/20 0.31
MGLL Q99685 1/20 0.31
NISCH Q9Y2I1 1/20 0.31
DAO P14920 1/20 0.31
LMNA P02545 1/20 0.31
GLA P06280 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482161 0.88 LIPG (0.43) LIPG
SCHEMBL975133 0.86 LIPG (0.50) LIPGPPARGPPARA
SCHEMBL2101331 0.84 LIPG (0.53) LIPGPPARGPPARAHTTMEN1
SCHEMBL29199586 0.84 LIPG (0.53) LIPGPPARGPPARAHTTMEN1
SCHEMBL29199609 0.84 LIPG (0.53) LIPGPPARGPPARAHTTMEN1
SCHEMBL21383030 0.83 LIPG (0.32) LIPGADRA2BADRA2CADRA2APPARG
SCHEMBL115194 0.82 MGLL (0.42) GAAALDH1A1MGLLLMNAMAPT
SCHEMBL21383134 0.78 LIPG (0.33) LIPGADRA2BADRA2CADRA2AHTR1A
SCHEMBL1780725 0.78 LIPG (0.37) LIPGADRA2BADRA2CADRA2APPARG
SCHEMBL6114355 0.78 LIPG (0.33) LIPGADRA2BADRA2CADRA2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768732-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY Dow Global Technologies LLC (US) 2021-01-27 EP disclosed
EP-3768733-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME Dow Global Technologies LLC (US) 2021-01-27 EP disclosed
US-20210017311-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME DOW GLOBAL TECHNOLOGIES LLC 2021-01-21 US disclosed
US-20210017195-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY DOW GLOBAL TECHNOLOGIES LLC (US) 2021-01-21 US disclosed
CN-111868109-A Method for functionalizing organozinc compounds with halosilanes using basic nitrogen-containing heterocycles and silane-functionalized compounds prepared therefrom 陶氏环球技术有限责任公司 2020-10-30 CN disclosed
CN-111868110-A Silicon-terminated telechelic polyolefin compositions and methods of making the same 陶氏环球技术有限责任公司 2020-10-30 CN disclosed
WO-2019182993-A1 SILICON-TERMINATED TELECHELIC POLYOLEFIN COMPOSITIONS AND PROCESSES FOR PREPARING THE SAME DOW GLOBAL TECHNOLOGIES LLC (US) 2019-09-26 WO disclosed
WO-2019182992-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY DOW GLOBAL TECHNOLOGIES LLC (US) 2019-09-26 WO disclosed
EP-2128897-B1 SILICON DIELECTRIC TREATING AGENT FOR USE AFTER ETCHING, PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJITSU LTD (JP) 2015-05-06 EP disclosed
EP-2599836-B1 CURABLE COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION ADEKA CORP (JP) 2015-03-25 EP disclosed
US-8716209-B2 Agent for post-etch treatment of silicon dielectric film, method of manufacturing semiconductor device, and semiconductor device FUJITSU LIMITED (JP) 2014-05-06 US disclosed
US-8470937-B2 Curable composition for semiconductor encapsulation ADEKA CORPORATION (JP) 2013-06-25 US disclosed
EP-2599836-A1 CURABLE COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION Adeka Corporation (JP) 2013-06-05 EP disclosed
US-20120126435-A1 CURABLE COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION ADEKA CORPORATION (JP) 2012-05-24 US disclosed
US-20100007031-A1 AGENT FOR POST-ETCH TREATMENT OF SILICON DIELECTRIC FILM, METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJITSU LIMITED (JP) 2010-01-14 US disclosed
EP-2128897-A1 SILICON DIELECTRIC TREATING AGENT FOR USE AFTER ETCHING, PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE Fujitsu Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017195-A1 PROCESS FOR FUNCTIONALIZATION OF ORGANO-ZINC COMPOUNDS WITH HALOSILANES USING BASIC NITROGEN CONTAINING HETEROCYCLES AND SILYL-FUNCTIONALIZED COMPOUNDS PREPARED THEREBY ZRANB2, NISCH, ZKSCAN2 LIPG 3251/4885ADRA2B 3695/4885ADRA2C 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.